|
|
Wittkowski, K. M. (1988). Über die Bedeutung von Detergentien für die HIV-Prophylaxe unter Heterosexuellen. AIDS-Forschung, 7, 401–403.
Keywords: health promotion; Aids; HIV infection
|
|
|
|
Coppola, R. C., Manconi, P. E., Piro, R., Di Martino, M. L., & Masia, G. (1994). HCV, HIV, HBV and HDV infections in intravenous drug addicts. European Journal of Epidemiology, 10, 279–283.
Abstract: Hepatitis viruses and the acquired immunodeficiency viruses often infect intravenous drug addicts (IVDAs). Our study includes 255 IVDAs (26 females and 229 males, aged 20–35 years) from Cagliari. Of 255 subjects examined, 207 (81.1%) were positive for anti-HCV and 84 (32.9%) for anti-HIV. Nineteen (7.4%) subjects were HBsAg carriers, and 12 of these (63%) had an HDV super-infection. Markers of previous HBV infections were tested in 223 cases and 137 (61.4%) were found positive; of these 14 (10.2%) also had HDV infection. Of the 223 drug addicts examined for all infection markers, 18 (8%) were negative to all markers, 46 (20.6%) were positive to only one, 89(39.9%) were positive to two, 64 (28.7%) to three and 6 (2.6%) were positive to all. Subjects with a single infection were significantly fewer than those with multiple infections. The correlations studied among the various markers did not point out any statistically significant associations. Even so, a previous HBV infection was more common while active HBV/HDV infections were less common among subjects with anti-HCV; HDV infection was more common among HIV-positive subjects. In HBsAg carriers neither HBV-DNA nor HCV-RNA was detected; HCV-RNA was found more frequently in anti-HIV positive subjects than in subjects with the anti-HCV isolate.
Keywords: health promotion; HIV infection; Aids
|
|
|
|
Roos, B., Somaini, B., Osterwalder, J., & Billo, N. (1988). HIV-Kontagiosität : Manchmal kein Thema. Schweizer Apothekerzeitung, 13(30.03.1988).
Keywords: health promotion; HIV infection; Aids
|
|
|
|
Steinmüller, J. (2003). Neue Therapieoptionen bei Hepatitis C : Sonderdruck. Suchtmedizin in Forschung und Praxis, 5(2), 146–147.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
|
Schreier, E., & Höhne, M. (2001). Hepatitis C : Epidemiologie und Prävention. Bundesgesundheitsblatt : Gesundheitsforschung : Gesundheitsschutz, 44, 554–561.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
|
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., et al. (2002). Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV international Panel. Aids, 16, 813–828.
Keywords: health promotion; viral hepatitis; hepatitis C; HIV infection; Aids
|
|
|
|
Leshel-Hauzeneder, M. (2003). Sonderbericht Hepatitis C : Hepatitis-C-Infektionen ausheilen : Pegyliertes lnterferon -alfa- 2a schafft neue Perspektiven in Deutschland. MMW : Fortschritte der Medizin, 145(26), 52–53.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
|
Böttcher-Bühler, E., & Szostecki, C. (2002). Sonderbericht Chronische Hepatitis C : Pegyliertes Interferon U-2a : Lebensqualitat steigt bei erfolgreicher Therapie deutlich an. MMW : Fortschritte der Medizin, 144(48), 52–53.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
|
Huber, M., Oppliger, R., Vernazza, P., Schönbucher, P., Bertisch, B., Meili, D., et al. (2002). Therapie der Chronischen Hepatitis C in offiziellen Opiat Substitutionsprogrammen : Interferon alfa 2a in Kombination mit Ribavirin in hoher oder niedriger Dosis : eine offene, randomisierte Multizenterstudie. Suchtmedizin in Forschung und Praxis, 4(2), 84–85.
|
|
|
|
Huber, M., Weber, R., Oppliger, R., Vernazza, P., Schmid, P., Schönbucher, P., et al. (2005). Interferon-alpha2a plus ribavirin 1000/1200 mg versus interferon-alpha2a plus ribavirin 600 mg for treatment of chronic hepatitis C among patients in opiate substitution programs : an open-label randomized multicenter trial : Korrekturexemplar. Infection, 33(1), 93–97.
Abstract: Background: Many intravenous opiate users are infected with hepatitis C virus (HCV) but few are treated. Although this complies with various guidelines, virtually no published evidence supports such a recommendation. Patients and Methods: In a multicenter study, HCV-infected patients in opiate maintenance treatment programs received interferon plus high- or low-dose ribavirin (1000/1200 mg or 600 mg). HIV-coinfected patients were not included. Endpoints were feasibility, efficacy, side effects, and reasons for dropout. Results: Of the 420 patients who tested positive for HCV, 27 (6%) were enrolled; 393 (94%) either failed to meet the inclusion criteria or refused treatment. Virologic end-of-treatment response was achieved in 12/27 patients, and sustained response in 13/27 (48%). Response depended on viral genotype, not ribavirin dose. The two doses of ribavirin did not differ in their side effects. Conclusion: In a small fraction of HCV-infected intravenous drug users in an opiate maintenance treatment program, antiviral therapy was feasible, safe and effective. The success rate was comparable to that achieved in controlled studies that excluded drug users.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
